Shivani Patel, MD
Rheumatology · Fullerton, CANPI 1487946364
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,796 of the $37,560 with a category attached, or 68.7%. Pfizer accounts for 70.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $26,857 and has fallen 90.5% since, to $2,544 in 2025.
Across 584 payments — averaging $64.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$27K
- Amgen$3K
- AbbVie$2K
- Johnson & Johnson$2K
- Novartis$891
- GSK$858
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$25,79669%
- Food & beverage$11,75031%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 41 | $26,509 |
| Amgen(2 entities) | 172 | $2,963 |
| AbbVie | 140 | $2,289 |
| Johnson & Johnson | 86 | $2,078 |
| Novartis | 46 | $891 |
| GSK | 30 | $858 |
| Boston Scientific | 6 | $399 |
| UCB, Inc. | 7 | $294 |
| Lilly USA, LLC | 12 | $266 |
| E.r. Squibb & Sons, L.L.C. | 8 | $236 |
| AstraZeneca | 8 | $170 |
| Radius Health, Inc. | 5 | $125 |
| Sanofi | 2 | $86 |
| Scilex Pharmaceuticals Inc. | 4 | $62 |
| Aurinia Pharma U.S., Inc. | 3 | $54 |
| Shield Therapeutics Inc | 2 | $52 |
| Nabriva Therapeutics, PLC | 1 | $46 |
| Bristol Myers Squibb | 2 | $39 |
| Antares Pharma, Inc. | 2 | $34 |
| Genentech USA, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Sandoz | 1 | $14 |
| Organon | 1 | $13 |
| Medexus Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,560 in reported general payments places this provider in the 85th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 26 | $255,113 |
| Xeljanz XrTofacitinib Citrate | 15 | $130,092 |
| Hydroxychloroquine Sulfate | 165 | $11,298 |
| Diclofenac Sodium | 47 | $5,992 |
| MethotrexateMethotrexate Sodium | 91 | $4,633 |
| Leflunomide | 41 | $4,457 |
| Celecoxib | 41 | $2,793 |
| Febuxostat | 11 | $1,977 |
| Alendronate Sodium | 51 | $1,862 |
| Prednisone | 88 | $1,100 |
| Gabapentin | 69 | $1,007 |
| Duloxetine Hcl | 27 | $760 |
| Methylprednisolone | 39 | $633 |
| Cyclobenzaprine Hcl | 61 | $552 |
| Sulfasalazine | 11 | $390 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Fullerton
- Shirley PangFullerton$131K
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.